Skip to main content
. 2016 Mar 15;33(4):643–657. doi: 10.1007/s12325-016-0313-x

Fig. 3.

Fig. 3

Unadjusted and adjusted Kaplan–Meier OS curves for vemurafenib vs. observed OS curve for talimogene laherparepvec, all patients. OS overall survival, T-VEC talimogene laherparepvec